Metabolic Reprogramming of Stromal Fibroblasts through p62-mTORC1 Signaling Promotes Inflammation and Tumorigenesis
The tumor microenvironment plays a critical role in cancer progression, but the precise mechanisms by which stromal cells influence the epithelium are poorly understood. Here we show that p62 levels were reduced in the stroma of several tumors and that its loss in the tumor microenvironment or strom...
Saved in:
Published in | Cancer cell Vol. 26; no. 1; pp. 121 - 135 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
14.07.2014
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The tumor microenvironment plays a critical role in cancer progression, but the precise mechanisms by which stromal cells influence the epithelium are poorly understood. Here we show that p62 levels were reduced in the stroma of several tumors and that its loss in the tumor microenvironment or stromal fibroblasts resulted in increased tumorigenesis of epithelial prostate cancer cells. The mechanism involves the regulation of cellular redox through an mTORC1/c-Myc pathway of stromal glucose and amino acid metabolism, resulting in increased stromal IL-6 production, which is required for tumor promotion in the epithelial compartment. Thus, p62 is an anti-inflammatory tumor suppressor that acts through the modulation of metabolism in the tumor stroma.
[Display omitted]
•p62 levels are reduced in mouse and human tumor stroma•p62 loss in stromal fibroblasts resulted in increased epithelial tumorigenesis•p62 regulates stromal inflammation by mTor/c-Myc metabolic reprogramming•Stromal metabolic reprogramming is essential for IL-6-driven epithelial tumorigenesis
Valencia et al. show that reduced levels of p62 in cancer-associated fibroblasts increase prostate epithelial cell cancer tumorigenesis. They show that p62 modulates stromal cell glucose and amino acid metabolism through an mTORC1/c-Myc pathway, resulting in increased secretion of tumor-promoting IL-6. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1535-6108 1878-3686 |
DOI: | 10.1016/j.ccr.2014.05.004 |